-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The 2021 American Society of Clinical Oncology (ASCO) annual meeting will be held online from June 4 to June 8.
The ASCO annual meeting is one of the most influential academic annual meetings in the field of oncology.
At that time, elite scholars in clinical oncology around the world will gather in the cloud to discuss the clinical development of oncology.
As the pioneer and leader of China's innovative drug research and development, Hengrui Medicine has re-registered a variety of research and development drugs in this international conference, covering breast cancer, gastrointestinal tumors, liver cancer, lung cancer, head and neck tumors and other fields.
Among them, the "Shuang Ai combination" (carrelizumab combined with apatinib) performed well, and a total of 14 studies were selected for the poster and abstract section of this conference.
Hepatobiliary tumors: Multi-line treatment progress and deeper exploration.
This "Shuang Ai Combination" has 5 studies in the field of liver cancer for data announcements and results updates.
Among them, the RESCUE study of carrelizumab combined with apatinib in the treatment of advanced hepatocellular carcinoma (HCC) led by Professor Jianming Xu updated the overall survival (OS) results.
The median OS of the first-line treatment cohort was 20.
1 months, 2 years The OS rate was 43.
3%, the median OS in the second-line treatment cohort was 21.
8 months, and the 2-year OS rate was 44.
6%, showing the benefits of the "double AI regimen" for advanced HCC1.
In addition, the team of Professor Gong Liansheng from Xiangya Hospital of Central South University also retrospectively analyzed the correlation between the clinical results of carrelizumab combined with apatinib in the treatment of unresectable HCC and patient characteristics, and a total of 26 patients with unresectable HCC were included.
The objective response rate (ORR) of the "double AI combination" is 57.
7%, the disease control rate (DCR) is 84.
62%, the median progression-free survival (PFS) is 11 months, and the median OS is 18.
2 months.
The study evaluated the efficacy of carrelizumab combined with apatinib in the real world, but a larger sample size and longer-term follow-up are still needed to verify the phase results2. In terms of "Shuang Ai combination" combined with other treatments, the team of Professor Xing Wenge from Tianjin Medical University Cancer Hospital's research design on the efficacy and safety of carrelizumab combined with apatinib combined with TACE and cryoablation in the first-line treatment of advanced HCC was selected into the poster Link, look forward to the announcement of future results3.
In terms of perioperative treatment, a prospective, phase II study evaluating the efficacy and safety of carrelizumab combined with apatinib in the perioperative treatment of HCC was selected for the poster presentation of this conference.
In 17 cases Of the patients undergoing surgery, 5 achieved major pathological remission (MPR)4.
The First Affiliated Hospital of Guangxi Medical University conducted a study to evaluate the prognosis of patients undergoing conversion hepatectomy after treatment with liver cancer with insufficient residual liver by portal vein ligation combined with apatinib and carrelizumab5.
In terms of efficacy biomarkers, a study explored the efficacy biomarkers of carrelizumab combined with apatinib in neoadjuvant treatment of locally advanced cholangiocarcinoma6.
In terms of other digestive system tumors, a phase Ib study of carrelizumab combined with apatinib neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma led by the Chinese Academy of Medical Sciences was included in the poster link.
After 29 cases of neoadjuvant treatment Among patients undergoing esophagectomy, 15 achieved MPR and 7 achieved pathological complete remission (pCR)7.
The team of Professor Liu Lian from Qilu Hospital of Shandong Province evaluated the application of carrelizumab combined with apatinib and S-1±oxaliplatin neoadjuvant therapy or conversion therapy in patients with locally advanced cT4a/bN+ gastric cancer.
The program also reveals the prospects of carrelizumab, apatinib, S-1±oxaliplatin neoadjuvant/conversion therapy in cT4a/bN+ gastric cancer patients8.
Lung cancer: combination therapy and exploration of more advanced patients In the field of lung cancer, a total of 1 poster and 2 online abstracts were selected for this ASCO conference.
Including the Zhao Mingfang team of the First Affiliated Hospital of China Medical University on the study design of carrelizumab monotherapy or combined with apatinib for the treatment of PD-L1-positive advanced pulmonary sarcomatoid carcinoma was selected for the poster of this conference, and we look forward to the announcement of follow-up research results 9 .
The team of Professor Liu Li and Professor Meng Rui from Union Hospital of Tongji Medical College of Huazhong University of Science and Technology on the treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC) after carrelizumab plus apatinib with or without body stereotactic radiotherapy ) Effectiveness studies have initially demonstrated the benefit of carrelizumab combined with apatinib± after radiotherapy for the treatment of EGFR-mutant NSCLC10.
The study by Professor Pan Yueyin from the First Affiliated Hospital of the University of Science and Technology of China included more patients with low PS scores and later disease stages, and evaluated carrelizumab combined with chemotherapy followed by sequential apatinib second-line treatment of advanced EGFR-negative lung glands Efficacy and safety in cancer patients11.
Multi-tumor species, Qi blossoming in other tumor treatment fields, Professor Zhong Laiping from the Ninth People’s Hospital Affiliated to Shanghai Jiaotong University School of Medicine launched a carrelizumab combined with apatinib induction therapy for resectable locally advanced oral squamous cell carcinoma The preliminary results of the study show that carrelizumab combined with apatinib is well tolerated, and the MPR rate is higher than that of traditional induction chemotherapy.
12
The team of Professor Guo Jun from Peking University Cancer Hospital announced the study of apatinib combined with carrelizumab in the treatment of advanced metastatic acral melanoma.
Among 27 patients with evaluable efficacy, the ORR rate was 22.
2% and the DCR The rate was 77.
8%, and the survival results are still under follow-up13.
In addition, in terms of new drug combination therapy, the team of Professor Cheng Ying from Jilin Cancer Hospital has carried out a phase I study of IDO inhibitor (SHR9146) plus carrelizumab with or without apatinib in the treatment of advanced solid tumors.
The safety of SHR9146 combined with carrelizumab ± apatinib in patients with advanced solid tumors is acceptable, and we look forward to the publication of further clinical research results14.
In addition to the above-mentioned "Shuang Ai" related treatment research progress, Hengrui Medicine has been selected for this ASCO meeting with a total of more than 60 studies, involving the field of multi-tumor treatment, with fruitful results.
The ASCO conference once again demonstrated to the world the strength of China's oncology clinical research and the rise of China's national pharmaceutical companies.
The publication and update of a number of research results will promote the development of my country's oncology field towards a higher and stronger goal, thereby benefiting more Chinese cancer patients.
The above research results are sourced from the official website of the 2021 ASCO annual meeting, as of May 26, 2021.
References (underlined view all_) 1.
Yun Zhang, Jianming Xu, Jie Shen, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr 4076).
2.
Gang Liu, Liansheng Gong, Wenxuan Zhou, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr e16120) 3.
Wenge Xing, Zhi Guo.
J Clin Oncol 39, 2021 (suppl 15; abstr TPS4160).
4.
Yongxiang Xia, Ping Wang, Liyong Pu, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr 4082).
5.
Zhiming Zeng, Guangzhi Zhu, Huasheng Huang, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr e16132)6.
Zhen Wang.
J Clin Oncol 39, 2021 (suppl 15; abstr 4047).
7.
Song Li, Wenbin Yu, Fei Xie, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr 4061).
8.
Jian-hua Rao, Chen Wu, Hui Zhang, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr e16126).
9.
Mingfang Zhao, Tao Han.
J Clin Oncol 39 , 2021 (suppl 15; abstr TPS9130).
10.
Rui Meng, Lu Wu, Kai Zhang, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr e21128).
11.
Yueyin Pan, Fengshou Jiang, Yingying Du, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr e21051).
12.
Lai-Ping Zhong, Wu -tong Ju, Rong-hui Xia, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr 6052).
13.
Xuan Wang, Chuanliang Cui, Bin Lian, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr 9539).
14.
Ying Cheng, Ying Liu, Jinhua Xu, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr 3101).
※ Please note that the answers or content provided in this document may not include All relevant information.
2021 (suppl 15; abstr 3101).
※ Please note that the answers or content provided in this document may not contain all relevant information.
2021 (suppl 15; abstr 3101).
※ Please note that the answers or content provided in this document may not contain all relevant information. This content is for reference only and is not a substitute for the advice of doctors or other medical and health professionals.
Patients should not use this information to diagnose health or disease status by themselves.
The ASCO annual meeting is one of the most influential academic annual meetings in the field of oncology.
At that time, elite scholars in clinical oncology around the world will gather in the cloud to discuss the clinical development of oncology.
As the pioneer and leader of China's innovative drug research and development, Hengrui Medicine has re-registered a variety of research and development drugs in this international conference, covering breast cancer, gastrointestinal tumors, liver cancer, lung cancer, head and neck tumors and other fields.
Among them, the "Shuang Ai combination" (carrelizumab combined with apatinib) performed well, and a total of 14 studies were selected for the poster and abstract section of this conference.
Hepatobiliary tumors: Multi-line treatment progress and deeper exploration.
This "Shuang Ai Combination" has 5 studies in the field of liver cancer for data announcements and results updates.
Among them, the RESCUE study of carrelizumab combined with apatinib in the treatment of advanced hepatocellular carcinoma (HCC) led by Professor Jianming Xu updated the overall survival (OS) results.
The median OS of the first-line treatment cohort was 20.
1 months, 2 years The OS rate was 43.
3%, the median OS in the second-line treatment cohort was 21.
8 months, and the 2-year OS rate was 44.
6%, showing the benefits of the "double AI regimen" for advanced HCC1.
In addition, the team of Professor Gong Liansheng from Xiangya Hospital of Central South University also retrospectively analyzed the correlation between the clinical results of carrelizumab combined with apatinib in the treatment of unresectable HCC and patient characteristics, and a total of 26 patients with unresectable HCC were included.
The objective response rate (ORR) of the "double AI combination" is 57.
7%, the disease control rate (DCR) is 84.
62%, the median progression-free survival (PFS) is 11 months, and the median OS is 18.
2 months.
The study evaluated the efficacy of carrelizumab combined with apatinib in the real world, but a larger sample size and longer-term follow-up are still needed to verify the phase results2. In terms of "Shuang Ai combination" combined with other treatments, the team of Professor Xing Wenge from Tianjin Medical University Cancer Hospital's research design on the efficacy and safety of carrelizumab combined with apatinib combined with TACE and cryoablation in the first-line treatment of advanced HCC was selected into the poster Link, look forward to the announcement of future results3.
In terms of perioperative treatment, a prospective, phase II study evaluating the efficacy and safety of carrelizumab combined with apatinib in the perioperative treatment of HCC was selected for the poster presentation of this conference.
In 17 cases Of the patients undergoing surgery, 5 achieved major pathological remission (MPR)4.
The First Affiliated Hospital of Guangxi Medical University conducted a study to evaluate the prognosis of patients undergoing conversion hepatectomy after treatment with liver cancer with insufficient residual liver by portal vein ligation combined with apatinib and carrelizumab5.
In terms of efficacy biomarkers, a study explored the efficacy biomarkers of carrelizumab combined with apatinib in neoadjuvant treatment of locally advanced cholangiocarcinoma6.
In terms of other digestive system tumors, a phase Ib study of carrelizumab combined with apatinib neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma led by the Chinese Academy of Medical Sciences was included in the poster link.
After 29 cases of neoadjuvant treatment Among patients undergoing esophagectomy, 15 achieved MPR and 7 achieved pathological complete remission (pCR)7.
The team of Professor Liu Lian from Qilu Hospital of Shandong Province evaluated the application of carrelizumab combined with apatinib and S-1±oxaliplatin neoadjuvant therapy or conversion therapy in patients with locally advanced cT4a/bN+ gastric cancer.
The program also reveals the prospects of carrelizumab, apatinib, S-1±oxaliplatin neoadjuvant/conversion therapy in cT4a/bN+ gastric cancer patients8.
Lung cancer: combination therapy and exploration of more advanced patients In the field of lung cancer, a total of 1 poster and 2 online abstracts were selected for this ASCO conference.
Including the Zhao Mingfang team of the First Affiliated Hospital of China Medical University on the study design of carrelizumab monotherapy or combined with apatinib for the treatment of PD-L1-positive advanced pulmonary sarcomatoid carcinoma was selected for the poster of this conference, and we look forward to the announcement of follow-up research results 9 .
The team of Professor Liu Li and Professor Meng Rui from Union Hospital of Tongji Medical College of Huazhong University of Science and Technology on the treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC) after carrelizumab plus apatinib with or without body stereotactic radiotherapy ) Effectiveness studies have initially demonstrated the benefit of carrelizumab combined with apatinib± after radiotherapy for the treatment of EGFR-mutant NSCLC10.
The study by Professor Pan Yueyin from the First Affiliated Hospital of the University of Science and Technology of China included more patients with low PS scores and later disease stages, and evaluated carrelizumab combined with chemotherapy followed by sequential apatinib second-line treatment of advanced EGFR-negative lung glands Efficacy and safety in cancer patients11.
Multi-tumor species, Qi blossoming in other tumor treatment fields, Professor Zhong Laiping from the Ninth People’s Hospital Affiliated to Shanghai Jiaotong University School of Medicine launched a carrelizumab combined with apatinib induction therapy for resectable locally advanced oral squamous cell carcinoma The preliminary results of the study show that carrelizumab combined with apatinib is well tolerated, and the MPR rate is higher than that of traditional induction chemotherapy.
12
The team of Professor Guo Jun from Peking University Cancer Hospital announced the study of apatinib combined with carrelizumab in the treatment of advanced metastatic acral melanoma.
Among 27 patients with evaluable efficacy, the ORR rate was 22.
2% and the DCR The rate was 77.
8%, and the survival results are still under follow-up13.
In addition, in terms of new drug combination therapy, the team of Professor Cheng Ying from Jilin Cancer Hospital has carried out a phase I study of IDO inhibitor (SHR9146) plus carrelizumab with or without apatinib in the treatment of advanced solid tumors.
The safety of SHR9146 combined with carrelizumab ± apatinib in patients with advanced solid tumors is acceptable, and we look forward to the publication of further clinical research results14.
In addition to the above-mentioned "Shuang Ai" related treatment research progress, Hengrui Medicine has been selected for this ASCO meeting with a total of more than 60 studies, involving the field of multi-tumor treatment, with fruitful results.
The ASCO conference once again demonstrated to the world the strength of China's oncology clinical research and the rise of China's national pharmaceutical companies.
The publication and update of a number of research results will promote the development of my country's oncology field towards a higher and stronger goal, thereby benefiting more Chinese cancer patients.
The above research results are sourced from the official website of the 2021 ASCO annual meeting, as of May 26, 2021.
References (underlined view all_) 1.
Yun Zhang, Jianming Xu, Jie Shen, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr 4076).
2.
Gang Liu, Liansheng Gong, Wenxuan Zhou, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr e16120) 3.
Wenge Xing, Zhi Guo.
J Clin Oncol 39, 2021 (suppl 15; abstr TPS4160).
4.
Yongxiang Xia, Ping Wang, Liyong Pu, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr 4082).
5.
Zhiming Zeng, Guangzhi Zhu, Huasheng Huang, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr e16132)6.
Zhen Wang.
J Clin Oncol 39, 2021 (suppl 15; abstr 4047).
7.
Song Li, Wenbin Yu, Fei Xie, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr 4061).
8.
Jian-hua Rao, Chen Wu, Hui Zhang, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr e16126).
9.
Mingfang Zhao, Tao Han.
J Clin Oncol 39 , 2021 (suppl 15; abstr TPS9130).
10.
Rui Meng, Lu Wu, Kai Zhang, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr e21128).
11.
Yueyin Pan, Fengshou Jiang, Yingying Du, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr e21051).
12.
Lai-Ping Zhong, Wu -tong Ju, Rong-hui Xia, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr 6052).
13.
Xuan Wang, Chuanliang Cui, Bin Lian, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr 9539).
14.
Ying Cheng, Ying Liu, Jinhua Xu, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr 3101).
※ Please note that the answers or content provided in this document may not include All relevant information.
2021 (suppl 15; abstr 3101).
※ Please note that the answers or content provided in this document may not contain all relevant information.
2021 (suppl 15; abstr 3101).
※ Please note that the answers or content provided in this document may not contain all relevant information. This content is for reference only and is not a substitute for the advice of doctors or other medical and health professionals.
Patients should not use this information to diagnose health or disease status by themselves.
